Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

BACKGROUND: There are currently no approved treatments for the prodromal stage of Alzheimer’s disease (AD). Approved symptomatic treatments for mild-to-moderate AD include acetylcholinesterase inhibitors and memantine, but more efficacious treatments are needed. BI 409306 is a potent and selective p...

Descripción completa

Detalles Bibliográficos
Autores principales: Frölich, Lutz, Wunderlich, Glen, Thamer, Claus, Roehrle, Michael, Garcia, Miguel, Dubois, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371616/
https://www.ncbi.nlm.nih.gov/pubmed/30755255
http://dx.doi.org/10.1186/s13195-019-0467-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371616/
https://www.ncbi.nlm.nih.gov/pubmed/30755255
http://dx.doi.org/10.1186/s13195-019-0467-2

Ejemplares similares